A study published in the British Journal of Clinical Pharmacology demonstrated the bioequivalence of GP2015, a biosimilar etanercept treatment (Sandoz’s Erelzi), when delivered with an auto-injector and when delivered with pre-filled syringe in patients across a variety of body weights.
A study published in the British Journal of Clinical Pharmacology demonstrated the bioequivalence of GP2015, a biosimilar etanercept treatment (Sandoz’s Erelzi), when delivered with an auto-injector (AI) and when delivered with a pre-filled syringe (PFS) in patients across a variety of body weights.
According to the study’s authors, patients with rheumatoid arthritis (RA) may have difficulty self-administering pre-filled syringes due to the impact of RA on their dexterity, and may demonstrate greater adherence to therapy if provided with modes of administration that are convenient and easy to use. In June, Sandoz received approval from the European Commission (EC) for Erelzi, which is available in both the AI and PFS delivery devices. Sandoz announced that the product is now available to patients in Canada, where it is also sold in AI and PFS devices.
The study, which was conducted in healthy volunteers, compared PK in subjects who comprised a range of body weights. Secondary objectives of the study included comparison of additional PK parameters between the AI and PFS as well as the safety and tolerability of GP2015.
The study was designed as an open-label, randomized, 2-way, crossover study with 2 treatment periods. The subjects (n = 51) were healthy adult men who ranged in weight from 50 kg to 99.9 kg, and ranged in body mass index from 19.0 to 29.9. The subjects were randomized to receive a single, 50-mg subcutaneous injection of GP2015 via either AI or PFS during the first treatment period. After a wash-out period of 35 days or more, subjects received a single, 50-mg subcutaneous injection of GP2015 via either AI or PFS, whichever delivery method was the opposite of the first treatment period’s method. Twenty-five subjects were randomized to first receive AI dosing, and then to receive PFS dosing; 26 patients were randomized to first receive PFS, then AI. Outpatient visits were conducted up to day 19 to assess PK and safety. A follow-up visit was conducted 28 days after the second product administration. Two subjects did not complete the study (1 due to a protocol violation and 1 due to an adverse event).
Mean serum concentration-time profiles were found to be similar between the AI and PFS treatment administrations. Cmax, AUC0—tlast, and AUC0—inf were also found to be similar; the 90% confidence intervals for all 3 values were within the predefined bioequivalence range of 0.80 to 1.25. Furthermore, serum concentrations were similar across body weight categories, and the treatment’s half-life was identical (109 hours) between both administrations.
Incidence of treatment emergent adverse events (TEAEs) was identical between the study arms, the most frequently reported being headache, neutropenia, and rhinitis. Three subjects had mild injection-site reactions. All TEAEs were considered mild, and resolved during the study period.
The researchers concluded that AI and PFS deliver biosimilar etanercept in an equivalent way, and suggest that AI and PFS can be used interchangeably. The authors also note that no difference was observed in AI and PFS delivery across different weight groups, suggesting that both devices can be used in subjects with varying thickness of subcutaneous adipose tissue. The AI device, the researchers said, could offer advantages in terms of ease and convenience of use for patients across a range of body weights.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
June 27th 2024Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.
Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching
June 26th 2024Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.